Ani pharmaceuticals to acquire novitium pharma, strengthening r&d engine and expanding generics and cdmo business

Baudette, minn.--(business wire)--ani pharmaceuticals, inc. (“ani” or the “company”) (nasdaq: anip) today announced that it has signed a definitive agreement to acquire novitium pharma, a privately held, new jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities for $163.5 million, including $89.5 million in cash and $74 million in equity plus two potential future cash earn-outs of up to $46.5 million. the transaction has been approved by the ani
ANIP Ratings Summary
ANIP Quant Ranking